Evidence map›Paper›PMID 37538767›Full record

ArticleTurkish journal of chemistry2022

PEG4000 modified liposomes enhance the solubility of quercetin and improve the liposome functionality: in vitro characterization and the cellular efficacy.

Gülen Melike Demirbolat, Ömer Erdoğan, Göknil Pelin Coşkun, Özge Çevik

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Gülen Melike DemirbolatDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-5621-5818
Ömer ErdoğanDepartment of Biochemistry, School of Medicine, Aydın Adnan Menderes University, Aydın, Turkey.ORCID https://orcid.org/0000-0002-8327-7077
Göknil Pelin CoşkunDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-5168-3866
Özge ÇevikDepartment of Biochemistry, School of Medicine, Aydın Adnan Menderes University, Aydın, Turkey.ORCID https://orcid.org/0000-0002-9325-3757
Pharmaceutical Biotechnology (Czechia) · CZAdnan Menderes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quercetin, a multifunctional therapeutic agent, is used in various types of cancer. However, its therapeutic effect is limited by virtue of poorly aqueous solubility and instability in the physiological medium. To overcome these limitations, we aimed (i) to design quercetin loaded liposomes with unlinked-PEG4000 with regard to not only surface modification but also solubility enhancement, and (ii) to investigate the antineoplastic effects on HeLa cells. PEG4000 increased the quercetin solubility 2.2 fold. PEG4000 modified liposomes displayed small particle size (254 ± 69 nm), low polydispersity index (0.236 ± 0.018), favorable zeta potential (-35.4 ± 0.6 mV), high quercetin encapsulation efficiency (87.6 ± 5.6%), and drug loading (22.2 ± 6.9%). The homogeneity and particle size of stable PEGylated liposomes were proved by transmission electron microscopy. The drug release was reached up to 65.1 ± 3.8% in 6 h. The IC

Indexed as

antitumoral effectdrug deliverymitochondrial apoptosisPEGylated liposomesQuercetinsolubility

Identifiers

PMID37538767
PMCPMC10395731
OpenAlexW4290005338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.